Drug delivery of anticancer agents: Water soluble 4-poly (ethylene glycol) derivatives of the lignan, podophyllotoxin

Journal of Controlled Release

Volumn 61, Issue 3, 1999, Pages 281-294

  Greenwald, Richard B ^a   Conover, Charles D ^a   Pendri, Annapurna ^a   Choe, Yun H ^a   Martinez, Anthony ^a   Wu, Dechun ^a   Guan, Shuiyun ^a   Yao, Zuliang ^a   Shum, Kwok L ^a  

^a Enzon Incorporated   (United States)

Author keywords

Cancer; Conjugates; Delivery; Podophyllotoxin; Polyethylene glycol

Indexed keywords

ANTINEOPLASTIC AGENT; EPIPODOPHYLLOTOXIN; MACROGOL; PODOPHYLLOTOXIN;

ARTICLE; CONJUGATE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; HUMAN; HUMAN CELL; HYDROLYSIS; LUNG TUMOR; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA P388; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PODOPHYLLOTOXIN; POLYETHYLENE GLYCOLS; SOLUBILITY; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; WATER;

EID: 0032878627     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00153-4     Document Type: Article

References (24)

1. Ward R.S. The synthesis of lignans and neolignans. Chem. Soc. Rev. 11:1982;75-125.
2. Sackett D.L. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. Pharmac. Ther. 59:1993;163-228.
3. Greenspan E.M., Colsky J., Schoenbach E.B., Shear M.J. Response of patients with advanced neoplasms to the intravenous administration of α-peltatin. J. Natl. Cancer Inst. 14:1954;1257-1275.
4. Seidlova-Masinova V., Malinsky J., Santavy F. The biological effects of some podophyllin compounds and their dependence on chemical structure. J. Natl. Cancer Inst. 18:1957;359-369.
5. Stahelin H.F., Von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial lecture. Cancer Res. 51:1991;5-15.
6. Kreis W., Soricelli A. Comparison of a water-soluble and a water insoluble podophyllotoxin derivative in murine neoplasms. J. Cancer Res. Clin. Oncol. 95:1979;233-237.
7. Levy R.K., Hall I.H., Lee K.-H. Antitumor agents LXII: synthesis and biological evaluation of podophyllotoxin esters and related derivatives. J. Pharm. Sci. 72:1983;1158-1161.
8. Greenwald R.B., Gilbert C.W., Pendri A., Xia J., Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39:1996;424-431.
9. Greenwald R.B., Pendri A., Conover C.D., et al. Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg. Med. Chem. 6:1998;551-562.
10. Pendri A., Conover C.D., Greenwald R.B. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly (ethylene glycol): a water soluble prodrug. Anti-cancer Drug Des. 13:1998;387-395.
11. Conover C.D., Pendri A., Lee C., Gilbert C.W., Shum K.L., Greenwald R.B. Camptothecin delivery systems: the antitumor activity of a camptothecin-20-polyethylene glycol ester transport form. Anticancer Res. 117:1997;3361-3368.
12. Gensler W.J., Gastonis C.D. The podophyllotoxin-picropodophyllin equilibrium. J. Org. Chem. 31:1966;3224-3227.
13. Corbett T., Valeriote F., Polin L., et al. Discovery of solid tumor active agents using a soft-agar-colony formation disk-diffusion-assay. Valeriote F., Corbett T., Baker L. Cytotoxic Anticancer Drugs: Models And Concepts For Drug Discovery And Development. 1992;59-87 Kluwer Academic, Boston, Dordrecht, London.
14. Conover C.D., Greenwald R.B., Pendri A., Gilbert C.W., Shum K.L. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer. Chemother. Pharmacol. 42:1998;407-414.
15. Pedley R., Boden J., Boden R., Begent R., Turner A., Haines A., King D. The potential for enhanced tumour localisation of poly (ethylene glycol) modification of anti-CEA antibody. Br. J. Cancer. 70:1994;1126-1130.
16. Eno-Amooquaye E., Searle F., Boden J., Sharma S., Burke P. Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol. Br. J. Cancer. 73:1996;1323-1327.
17. Maeda H., Seymour L., Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:1992;351-362.
18. Murakami Y., Tabata Y., Ikada Y. Tumor accumulation of poly (ethylene glycol) with different molecular weights after intravenous injection. Drug Deliv. 4:1997;23-31.
19. Kelly M.G., Hartwell J.L. The biological effects and the chemical composition of podophyllin: a review. J. Natl. Cancer Inst. 14:1954;967-1010.
20. Jardine I. Podophllotoxin. Cassady J.M., Douros J.D. Anticancer Agents Based on Natural Product Models. 1980;319-351 Academic Press, New York, NY.
21. Takakura Y., Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 13:1996;820-831.
22. Brewer C.F., Loike J.D., B Horwitz S. Conformational analysis of podophyllotoxin and its congeners: Structure-activity relationship in microtubule assembly. J. Med. Chem. 22:1979;215-221.
23. Damayanthi Y., Lown J. Podophyllotoxins: current status and recent developments. Curr. Med. Chem. 5:1998;205-252.
24. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83:1994;601-606.